Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxis

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 101, Issue 3, 2007, Pages 226-230

  Edstein, M D ^a   Nasveld, P E ^a   Kocisko, D A ^a   Kitchener, S J ^a   Gatton, M L ^b   Rieckmann, K H ^a  

^a AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Adverse events; Gender; Malaria; Plasmodium vivax; Tafenoquine

Indexed keywords

DOXYCYCLINE; TAFENOQUINE;

ABDOMINAL DISCOMFORT; ADULT; AGE; ARTICLE; AUSTRALIA; BODY HEIGHT; BODY WEIGHT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALE; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; SEX DIFFERENCE; SINGLE DRUG DOSE; VOLUNTEER; VOMITING;

ADULT; AMINOQUINOLINES; ANTIMALARIALS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALARIA, VIVAX; MALE; NAUSEA; SEX CHARACTERISTICS;

PLASMODIUM VIVAX;

EID: 33846026765     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2006.04.003     Document Type: Article

References (22)

1. Baird J.K., and Rieckmann K.H. Can primaquine therapy for vivax malaria be improved?. Trends Parasitol. 19 (2003) 115-120
2. Brueckner R.P., Lasseter K.C., and Lin E.T. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am. J. Trop. Med. Hyg. 58 (1998) 645-649
3. Brueckner R.P., Ohrt C., Baird K., and Milhous W.K. 8-Aminoquinolines. In: Rosenthal P.J. (Ed). Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery (2000), Humana Press Inc., Totowa, NJ
4. Clayman C.B., Arnold J., Hockwald R.S., Yount E.H., Edgcomb Jr. J.H., and Alving A.S. Toxicity of primaquine in Caucasians. J. Am. Med. Assoc. 149 (1952) 1563-1568
5. Clyde D.F. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull. World Health Organ. 159 (1981) 391-395
6. Conrad K.A., and Kiser W.R. Doxycycline vs. mefloquine. Mil. Med. 162 (1997) viii
7. Edstein M.D., Kocisko D.A., Brewer T.G., Walsh D.S., Eamsila C., and Charles B.G. Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers. Br. J. Clin. Pharmacol. 52 (2001) 663-670
8. Edstein M.D., Kocisko D.A., Walsh D.S., Eamsila C., Charles B.G., and Rieckmann K.H. Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in Thai soldiers on monthly prophylaxis. Clin. Infect. Dis. 37 (2003) 1654-1658
9. Hale B.R., Owusu-Agyei S., Fryauff D.J., Koram K.A., Adjuik M., Oduro A.R., Prescott W.R., Baird J.K., Nkrumah F., Ritchie T.L., Franke E.D., Binka F.N., Horton J., and Hoffman S.L. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin. Infect. Dis. 36 (2003) 541-549
10. Karbwang J., and White N.J. Clinical pharmacokinetics of mefloquine. Clin. Pharmacokinet. 19 (1990) 264-279
11. Kocisko D.A., Walsh D.S., Eamsila C., and Edstein M.D. Measurement of tafenoquine (WR 238605) in human plasma, and venous and capillary blood by high-pressure liquid chromatography. Ther. Drug Monit. 22 (2000) 184-189
12. Lell B., Faucher J.F., Missinou M.A., Borrmann S., Dangelmaier O., Horton J., and Kremsner P.G. Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet 355 (2000) 2041-2045
13. Nasveld P., Kitchener S., Edstein M., and Rieckmann K. Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel. Trans. R. Soc. Trop. Med. Hyg. 96 (2002) 683-684
14. Pages F., Boutin J.-P., Meynard J.-B., Keundjian A., Ryfer S., Giurato L., and Baudon D. Tolerability of doxycycline monohydrate salt vs. chloroquine-proguanil in malaria chemoprophylaxis. Trop. Med. Int. Health 7 (2002) 919-924
15. Schlagenhauf P., Steffen R., Lobel H., Johnson R., Letz R., Tschopp A., Vranjes N., Bergqvist Y., Ericsson O., Hellgren U., Rombo L., Mannino S., Handschin J., and Sturchler D. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop. Med. Int. Health 1 (1996) 485-494
16. Schlagenhauf P., Tschopp A., Johnson R., Nothdurft H.D., Beck B., Schwartz E., Herold M., Krebs B., Veit O., Allwinn R., and Steffen R. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ 327 (2003) 1078-1083
17. Schwartz E., Potasman I., Rotenberg M., Almog S., and Sadetzki S. Serious adverse events of mefloquine in relation to blood level and gender. Am. J. Trop. Med. Hyg. 65 (2001) 189-192
18. Shanks G.D., Oloo A.J., Aleman G.M., Ohrt C., Klotz F.W., Braitman D., Horton J., and Brueckner R. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin. Infect. Dis. 33 (2001) 1968-1974
19. Simpson J.A., Price R., ter Kuile F.O., Teja-Isavatharm P., Nosten F., Aarons L., Chongsuphajaisiddhi T., Looareesuwan S., and White N.J. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin. Pharmacol. Ther. 66 (1999) 472-484
20. ter Kuile F.O., Nosten F., Luxemburger C., Kyle D., Teja-Isavatharm P., Phaipun L., Price R., Chongsuphajaisiddhi T., and White N.J. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull. World Health Organ. 73 (1995) 631-642
21. Walsh D.S., Looareesuwan S., Wilairatana P., Heppner Jr. D.G., Tang D.B., Brewer T.G., Chokejindachai W., Viriyavejakul P., Kyle D.E., Milhous W.K., Schuster B.G., Horton J., Braitman D.J., and Brueckner R.P. Randomized dose-ranging study of the safety and efficacy of WR238605 (tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J. Infect. Dis. 180 (1999) 1282-1287
22. Walsh D.S., Eamsila C., Sasiprapha T., Sangkharomya S., Khaewsathien P., Supakalin P., Tang D.B., Jarasrumgsichol P., Cherdchu C., Edstein M.D., Rieckmann K.H., and Brewer T.G. Efficacy of monthly tafenoquine for prophylaxis for Plasmodium vivax and multidrug-resistant P. falciparum malaria. J. Infect. Dis. 190 (2004) 1456-1463